246 related articles for article (PubMed ID: 36658481)
1. Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries.
Armuzzi A; Hart A; Cappelleri JC; Mammar N; Hur P; Hoskin B; Hennessy F; Milligan G; Dignass A
BMC Gastroenterol; 2023 Jan; 23(1):17. PubMed ID: 36658481
[TBL] [Abstract][Full Text] [Related]
2. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe.
Armuzzi A; Tarallo M; Lucas J; Bluff D; Hoskin B; Bargo D; Cappelleri JC; Salese L; daCosta DiBonaventura M
BMC Gastroenterol; 2020 Jan; 20(1):18. PubMed ID: 31964359
[TBL] [Abstract][Full Text] [Related]
3. Bowel Urgency in Patients with Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Real-World Survey in Japan.
Wang C; Ishizuka T; Tanaka M; Matsuo K; Knight H; Harvey N; Gillespie-Akar L; Gibble TH
Adv Ther; 2024 Jan; 41(1):431-450. PubMed ID: 37999831
[TBL] [Abstract][Full Text] [Related]
4. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
5. Rectal Urgency Among Patients With Ulcerative Colitis or Crohn's Disease: Analyses from a Global Survey.
Ha C; Naegeli AN; Lukanova R; Shan M; Wild R; Hennessy F; Jyothi Kommoju U; Potts Bleakman A; Hunter Gibble T
Crohns Colitis 360; 2023 Oct; 5(4):otad052. PubMed ID: 37928613
[TBL] [Abstract][Full Text] [Related]
6. Burden of Fatigue Among Patients with Ulcerative Colitis and Crohn's Disease: Results from a Global Survey of Patients and Gastroenterologists.
Regueiro M; Hunter T; Lukanova R; Shan M; Wild R; Knight H; Bannikoppa P; Naegeli AN
Adv Ther; 2023 Feb; 40(2):474-488. PubMed ID: 36370288
[TBL] [Abstract][Full Text] [Related]
7. Disease Activity and Health-related Quality of Life Relationships with Work Productivity in Patients with Ulcerative Colitis in OCTAVE Induction 1 and 2 and OCTAVE Sustain.
Targownik L; Dubinsky MC; Steinwurz F; Bushmakin AG; Cappelleri JC; Tai E; Gardiner S; Hur P; Panés J
J Crohns Colitis; 2023 Apr; 17(4):513-523. PubMed ID: 36271912
[TBL] [Abstract][Full Text] [Related]
8. Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry.
Herfarth HH; Afzali A; Fischer M; Hudesman D; Abdalla M; McCabe R; Cohen BL; Ungaro RC; Harlan W; Hanson J; Konijeti GG; Polyak S; Ritter T; Salzberg B; Seminerio J; English E; Zhang X; Long MD
Clin Transl Gastroenterol; 2024 Mar; 15(3):e00669. PubMed ID: 38131617
[TBL] [Abstract][Full Text] [Related]
9. Unmet Needs in Real-World Advanced Therapy-Naïve and -Experienced Patients with Moderately to Severely Active Ulcerative Colitis in the United States.
Afzali A; Lukanova R; Hennessy F; Kakehi S; Knight H; Milligan G; Gupte-Singh K
Adv Ther; 2023 Oct; 40(10):4321-4338. PubMed ID: 37458875
[TBL] [Abstract][Full Text] [Related]
10. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting.
Long MD; Afzali A; Fischer M; Hudesman D; Abdalla M; McCabe R; Cohen BL; Ungaro RC; Harlan W; Hanson J; Konijeti G; Polyak S; Ritter T; Salzberg B; Seminerio J; English E; Zhang X; Sharma PP; Herfarth HH
Inflamm Bowel Dis; 2023 Apr; 29(4):570-578. PubMed ID: 35700276
[TBL] [Abstract][Full Text] [Related]
11. Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database.
Chiorean M; Ha C; Hur P; Sharma PP; Gruben D; Khan NH
Dig Dis Sci; 2023 Oct; 68(10):3985-3993. PubMed ID: 37639057
[TBL] [Abstract][Full Text] [Related]
12. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
[TBL] [Abstract][Full Text] [Related]
13. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study.
Van Assche G; Peyrin-Biroulet L; Sturm A; Gisbert JP; Gaya DR; Bokemeyer B; Mantzaris GJ; Armuzzi A; Sebastian S; Lara N; Lynam M; Rojas-Farreras S; Fan T; Ding Q; Black CM; Kachroo S
Dig Liver Dis; 2016 Jun; 48(6):592-600. PubMed ID: 26935454
[TBL] [Abstract][Full Text] [Related]
14. Development and content validation of patient-reported outcomes tools for ulcerative colitis and Crohn's disease in adults with moderate-to-severe disease.
Nag A; Romero B
Health Qual Life Outcomes; 2022 May; 20(1):75. PubMed ID: 35525935
[TBL] [Abstract][Full Text] [Related]
15. P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
Parra Izquierdo V; Frias-Ordoñez J; Galindo P; Romero-Sanchez C; Florez C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S14-S15. PubMed ID: 37461974
[TBL] [Abstract][Full Text] [Related]
16. Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in Europe.
Gisbert JP; Streit P; Redondo I; Hartz S; Knight H; Quinones E; Harvey N; Palace V; Hunter Gibble T
Curr Med Res Opin; 2023 Sep; 39(9):1205-1214. PubMed ID: 37545338
[TBL] [Abstract][Full Text] [Related]
17. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
18. Improvements in Disease Activity Partially Mediate the Effect of Tofacitinib Treatment on Generic and Disease-Specific Health-Related Quality of Life in Patients with Ulcerative Colitis: Data from the OCTAVE Program.
Dubinsky MC; Armuzzi A; Gecse KB; Ullman T; Bushmakin AG; DiBonaventura M; Cappelleri JC; Connelly SB; Woolcott JC; Salese L
Dig Dis; 2023; 41(4):604-614. PubMed ID: 36603566
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
[TBL] [Abstract][Full Text] [Related]
20. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
